DeepMed Research

H. Lee Moffitt Cancer Center and Research Institute, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Electronic Social Network Assessment Program (eSNAP) + Caregiver Navigator

Not Applicable

Active, not recruiting

Conditions: Brain Cancer

Interventions: Behavioral: eSNAP
Behavioral: Caregiver Navigator

First Posted Date: 2020-02-13

Last Posted Date: 2025-04-17

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 296

Registration Number: NCT04268979

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

Barriers to Screening Breast MRI Utilization Among Patients at Elevated Risk

Completed

Conditions: Breast Cancer

Interventions: Behavioral: Qualitative Interviews
Behavioral: Self-Report Survey

First Posted Date: 2020-02-06

Last Posted Date: 2024-03-18

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 265

Registration Number: NCT04257474

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸
Georgetown Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States

Biological Outcomes of Pramlintide in Resectable Cutaneous Squamous Cell Carcinoma: A Pilot Study

Early Phase 1

Withdrawn

Conditions: Cutaneous Squamous Cell Carcinoma

Interventions: Drug: Pramlintide

First Posted Date: 2020-02-05

Last Posted Date: 2023-06-28

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Registration Number: NCT04252612

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

Cemiplimab-rwlc for Unresectable Locally Recurrent and/or Metastatic CSCC

Phase 2

Terminated

Conditions: Cutaneous Squamous Cell Carcinoma of the Head and Neck
Cutaneous Squamous Cell Carcinoma

Interventions: Drug: Cemiplimab-Rwlc

First Posted Date: 2020-01-27

Last Posted Date: 2022-11-04

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 3

Registration Number: NCT04242173

Locations: 🇺🇸
University of Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies

Phase 2

Completed

Conditions: Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Biphenotypic Acute Leukemia
Undifferentiated Leukemia
Prolymphocytic Leukemia
Myelodysplastic Syndromes
Lymphoplasmacytic Lymphoma
Chronic Myelogenous Leukemia
Myeloproliferative Neoplasm
Relapsed Large Cell Lymphoma

Interventions: Drug: Fludarabine
Drug: Melphalan
Radiation: Total Body Irradiation

First Posted Date: 2019-12-09

Last Posted Date: 2025-05-13

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 34

Registration Number: NCT04191187

Locations: 🇺🇸
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States

TGR-1202 (Umbralisib) in Treatment Naïve Patients With Chronic Lymphocytic Leukemia (CLL)

Phase 2

Terminated

Conditions: Chronic Lymphocytic Leukemia

Interventions: Drug: Umbralisib

First Posted Date: 2019-11-15

Last Posted Date: 2023-03-24

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 12

Registration Number: NCT04163718

Locations: 🇺🇸
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States

Daratumumab Based Response Adapted Therapy for Older Adults With Newly Diagnosed Multiple Myeloma

Phase 2

Active, not recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Daratumumab Injection
Drug: Dexamethasone Oral
Drug: Bortezomib Injection
Drug: Lenalidomide Pill

First Posted Date: 2019-11-05

Last Posted Date: 2025-02-07

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 33

Registration Number: NCT04151667

Locations: 🇺🇸
H. Lee Moffitt Cancer & Research Institute, Tampa, Florida, United States

Contrast-Enhanced Ultrasound for the Evaluation of Changes in Tumor Blood Flow Surrounding HAE

Early Phase 1

Terminated

Conditions: Liver Cancer
Hepatocellular Carcinoma

Interventions: Diagnostic Test: Lumason®

First Posted Date: 2019-11-05

Last Posted Date: 2023-04-10

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 4

Registration Number: NCT04150874

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

Developing and Testing a Spanish-Language Intervention to Reduce Cancer-Related Sleep Disturbance

Not Applicable

Completed

Conditions: Sleep Disturbance

Interventions: Behavioral: Spanish-language Cognitive-Behavioral Therapy for Insomnia (CBT-I) delivered via videoconference

First Posted Date: 2019-09-24

Last Posted Date: 2024-10-29

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 30

Registration Number: NCT04101526

Locations: 🇺🇸
H Lee Moffitt Cancer and Research Institute, Tampa, Florida, United States
🇵🇷
Ponce Health Services University, Ponce, Puerto Rico

Utilizing Augmented Reality as an Adjunct for Smoking Cessation

Not Applicable

Completed

Conditions: Smoking

Interventions: Behavioral: Augmented Reality 2
Behavioral: Augmented Reality 3
Behavioral: Augmented Reality 1
Behavioral: Augmented Reality 4

First Posted Date: 2019-09-24

Last Posted Date: 2023-05-22

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 197

Registration Number: NCT04101422

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy